Compare ELMT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMT | RLMD |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.9M | 515.2M |
| IPO Year | 2026 | 2012 |
| Metric | ELMT | RLMD |
|---|---|---|
| Price | $20.17 | $4.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.40 |
| AVG Volume (30 Days) | 282.0K | ★ 1.2M |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $12.49 | $0.60 |
| 52 Week High | $20.91 | $8.00 |
| Indicator | ELMT | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 66.50 | 35.72 |
| Support Level | $13.96 | $4.06 |
| Resistance Level | N/A | $4.97 |
| Average True Range (ATR) | 1.34 | 0.27 |
| MACD | 0.37 | 0.02 |
| Stochastic Oscillator | 95.96 | 25.71 |
The Elmet Group Co provides precision-engineered components and high-energy systems for the Aerospace, Defense and Government, Industrial, Medical, Semiconductor and Electronics, and Energy industries. The company is organized into two business divisions, Critical Materials Components and Engineered Microwave Products, offering a platform with expertise across interconnected markets. The company operates an integrated engineering-to-production system, covering custom design, development, and processing across Critical Materials and High-Power Microwave. Its Engineered Microwave capabilities helps to deliver tailored microwave energy solutions, while its Critical Materials expertise allows to design reliable solutions for some of the demanding environments in the world.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.